Literature DB >> 32829182

Evaluation and management of pulmonary arterial hypertension.

Sarah Beshay1, Sandeep Sahay2, Marc Humbert3.   

Abstract

Pulmonary arterial hypertension is a devastating progressive disease mediated by different pathophysiologic pathways that result in progressive increase in pulmonary vascular resistance along with right ventricular failure and eventually premature death. Despite significant advances in the understanding of the underlying mechanisms and development of a number of targeted therapies, pulmonary arterial hypertension remains a challenging condition with high morbidity and mortality. New therapies are being actively sought, and early recognition remains of paramount importance. In an effort to improve the detection and management of pulmonary hypertension, the 6th World Symposium on Pulmonary Hypertension came up with most recent statements in 2018. The goal of this review is to summarize some key updates from the proceedings of the Symposium pertaining to different aspects of evaluation and management of patients with pulmonary arterial hypertension.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Genetics; Patient perspectives; Pulmonary arterial hypertension; Pulmonary hypertension; Risk stratification; Treatment

Mesh:

Year:  2020        PMID: 32829182     DOI: 10.1016/j.rmed.2020.106099

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  9 in total

1.  An expert panel Delphi consensus statement on the use of palliative care in the management of patients with pulmonary arterial hypertension.

Authors:  Melisa Wilson; Rebekah H Anguiano; Rana L A Awdish; James C Coons; Amy Kimber; Melissa Morrison; Sara Paulus; Ann Schmit; Frank Spexarth; Keith M Swetz; Nathan J Verlinden; Mary E Whittenhall; Margaret R Sketch; Meredith Broderick; Jacqueline Brewer
Journal:  Pulm Circ       Date:  2022-01-05       Impact factor: 2.886

2.  Echocardiographic Evaluation of Initial Ambrisentan Plus Phosphodiesterase Type 5 Inhibitor on Right Ventricular Pulmonary Artery Coupling in Severe Pulmonary Arterial Hypertension Patients.

Authors:  Wei-Fang Lan; Yan Deng; Bin Wei; Kai Huang; Ping Dai; Shan-Shan Xie; Dan-Dan Wu
Journal:  Front Cardiovasc Med       Date:  2022-05-03

3.  Integrating haemodynamics identifies an extreme pulmonary hypertension phenotype.

Authors:  William M Oldham; Edward Hess; Stephen W Waldo; Marc Humbert; Gaurav Choudhary; Bradley A Maron
Journal:  Eur Respir J       Date:  2021-08-12       Impact factor: 33.795

4.  Sexual and Reproductive Health in Women with Pulmonary Hypertension: A Qualitative Study.

Authors:  Sabrina Cipolletta; Giorgia Ravasio; Maurizio Bussotti
Journal:  Arch Sex Behav       Date:  2022-02-14

Review 5.  The Role of Gut and Airway Microbiota in Pulmonary Arterial Hypertension.

Authors:  Linlin Huang; Hongdie Zhang; Yijun Liu; Yang Long
Journal:  Front Microbiol       Date:  2022-07-13       Impact factor: 6.064

6.  Integrative Proteomic and Phosphoproteomic Analyses of Hypoxia-Treated Pulmonary Artery Smooth Muscle Cells.

Authors:  Ang Luo; Rongrong Hao; Xia Zhou; Yangfan Jia; Haiyang Tang
Journal:  Proteomes       Date:  2022-06-28

Review 7.  An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers.

Authors:  Joana Santos-Gomes; Inês Gandra; Rui Adão; Frédéric Perros; Carmen Brás-Silva
Journal:  Front Cardiovasc Med       Date:  2022-07-14

8.  Comparative analysis of right ventricular metabolic reprogramming in pre-clinical rat models of severe pulmonary hypertension-induced right ventricular failure.

Authors:  Somanshu Banerjee; Jason Hong; Soban Umar
Journal:  Front Cardiovasc Med       Date:  2022-09-09

9.  Evaluation, Diagnosis, and Classification of Pulmonary Hypertension.

Authors:  Beshay Sarah; Guha Ashrith; Sahay Sandeep
Journal:  Methodist Debakey Cardiovasc J       Date:  2021-07-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.